Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tacrolimus sustained-release as initial therapy in CYP3A5 *3/*3 Chinese kidney transplant recipients
ChiCTR2600130790Phase 4Recruiting
- Sponsor
- The First Affiliated Hospital of Sun Yat-sen University
- Start
- Aug 2026
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tacrolimus in kidney allograft rejection, sponsored by The First Affiliated Hospital of Sun Yat-sen University. Primary endpoint: Rate of acute rejection at 24 weeks post transplantation. Started Aug 2026; status: recruiting.
02
Drugs
tacrolimus
03
Conditions
kidney allograft rejection
Beyond the preview
Go deeper on ChiCTR2600130790.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600130790.